Absci Corp.

Alan Bash is joining Legend Biotech as its president of Carvykti , an unconventional, newly-created role to oversee the commercial future of the biotech’s sole marketed cell therapy, among other aspects. Legend is developing Carvykti in partnership with Johnson & Johnson , which reported $286 million in sales in the third quarter. The BCMA-targeted cell therapy is expected to grow into a blockbuster multiple myeloma treatment — in large part as a result of a label expansion to earlier-line patients in April. Legend said in its press release that Bash’s new role will be to oversee Carvykti’s “commercial, technical operations, and quality functions.” Despite impressive results reported from the drug’s clinical studies, Legend and J&J have struggled to meet the commercial demand for the cell therapy. Carvykti has pulled ahead in a field that includes Bristol Myers Squibb ’s Abecma . But it faces an up-and-coming challenger in Gilead and Arcellx : The two companies announced on Tuesday that they had dosed the first patient in a Phase 3 trial of their experimental cell therapy anito-cel , which they say does not come with certain neurotoxicities reported with Carvykti. Bash had joined targeted therapeutics biotech ZielBio as CEO in early 2023. Before that, he was briefly head of Checkmate Pharmaceuticals as the immuno-oncology biotech sold to Regeneron for $250 million in cash. — Lei Lei Wu → Novo Nordisk said in its Q3 report that North America head Doug Langa will step aside at the end of the year “in order to focus on personal priorities and take up a role as senior advisor to Novo Nordisk’s executive management.” Novo has installed corporate development chief Dave Moore as the head of US commercial operations, while CFO Karsten Munk Knudsen will orchestrate the Danish pharma’s corporate strategy. Two days after the FDA declared that Ozempic and Wegovy were available in all doses, Novo’s semaglutide was on the march again, generating positive results in patients with metabolic dysfunction-associated steatohepatitis (MASH) and setting up a possible showdown with Madrigal Pharmaceuticals in an indication also referred to as NASH. → Moderna CEO Stéphane Bancel had been in charge of commercial operations since last December, when the company parted ways with chief commercial officer Arpa Garay . Bancel is now handing over those duties to president Stephen Hoge at Moderna, which made several other changes to its leadership team. Rose Loughlin , the SVP of research and early development, has been elevated to EVP of research. She came to Moderna from Biogen in 2016 as director of business development. Elsewhere, longtime GSK vet Jacqueline Miller has been promoted to CMO at the Covid vaccine titan after she had been SVP and therapeutic area head for infectious diseases. Finally, HR chief Tracey Franklin has expanded the scope of her responsibilities, becoming chief people and digital technology officer. She was chief HR talent and strategy officer at the end of her 14-year career at Merck . Moderna’s late entry into the RSV race produced only $10 million in third-quarter sales for the vaccine, miles behind the market leaders GSK and Pfizer , who haven’t exactly been scorching the nets themselves. But Moderna did turn in a profit as its shares $MRNA received a momentary boost before falling 3% on Thursday. → Axel Sven Malkomes will be the next CFO of German mRNA vaccine maker CureVac on Nov. 11. He succeeds Pierre Kemula , who just started his new CFO gig at Agomab . Malkomes is the ex-finance chief at two other German companies: Cardior Pharmaceuticals , the heart disease biotech that Novo Nordisk bought in March for $1.1 billion; and BioNTech ’s TCR partner Medigene . He’s also a board member at Cellectis . In July, CureVac said it would lay off 30% of its employees as GSK shelled out $429 million upfront for full control of the pair’s flu and Covid vaccine candidates. “It’s never nice to have this kind of news, but I do believe we need to do it now out of a position of financial strength,” CureVac CEO Alexander Zehnder told Endpoints News when the job cuts were announced. → Another notable CFO hire comes from Seaport Therapeutics , the Endpoints 11 winner that followed up its $100 million launch round with a $225 million Series B haul a few weeks ago. Lauren White had held this role for nine months at Elahere developer ImmunoGen , which was purchased by AbbVie for $10.1 billion . She landed her first CFO job at C4 Therapeutics in June 2021 after nine years at the Novartis Institutes for BioMedical Research . Are IPO plans not far behind? Time will tell. “I’m enjoying my brief hiatus as a private CEO right now,” Seaport chief Daphne Zohar said in an interview with Endpoints. → Swedish rare disease specialist Sobi has nominated David Meek as chairman of the board. Not long after Meek’s departure as CEO of Mirati , Bristol Myers swooped in to buy the company and its KRAS drug Krazati to compete with Amgen ’s Lumakras in the space. Meek has also held the top spot at Ipsen and FerGene , and has board seats at uniQure and Cullinan Therapeutics . → Mene Pangalos is the newest board member at Quotient Therapeutics , a Flagship joint that debuted last year and teamed up with Pfizer in August. Since his retirement from AstraZeneca , Pangalos has picked up a board seat at Absci and will join the board of directors at Biogen in January. He’s also on the scientific advisory board at Demis Hassabis ’ Isomorphic Labs. (By the way, check out this week’s Q&A with Hassabis and Andrew Dunn from the Financial Times ’ Global Pharma and Biotech Summit.) → After losing its former CEO Raj Kannan back in July, I-Mab has now locked Sean Fu into the position. Fu has been serving in the interim since Kannan’s exit. Prior to I-Mab, Fu was operating partner of ABio-X and CEO of RVAC Medicines and GeneLeap . Earlier in his career, Fu was with Merck, where he helped lead the integration work of the company following its $42 billion merger with Schering-Plough . It’s been quite a year for I-Mab: Back in April, the company officially spun out its China operations into a new company, I-Mab Biopharma (Hangzhou) , in a bid to win over investors. → Verrica Pharmaceuticals CEO Ted White is out after data for its basal cell carcinoma candidate VP-315 failed to move the needle with investors and job cuts affected 47 staffers. Verrica also drastically reduced its sales presence for its molluscum contagiosum drug Ycanth , from 80 sales territories to 35. In walks Jayson Rieger as president and CEO, and John Kirby as interim finance chief to lead a “leaner and more efficient operating structure,” as chairman Paul Manning put it . Rieger has spent more than a decade with PBM Capital , while Kirby is the former CFO of Aceragen and Idera Pharmaceuticals . → London-based protein degradation biotech Kesmalea Therapeutics has recruited Robert Johnson to steer the Syncona -backed company as CEO. Johnson’s résumé includes stints as CEO of Adrestia Therapeutics (acquired by Insmed ) and co-founder and CBO of Boston-based gene therapy company Affinia Therapeutics . → ElevateBio ’s gene editing sub Life Edit has welcomed Amy Pooler as SVP of R&D. Pooler was VP of neuroscience and head of research in her tenure with Sangamo Therapeutics . While ElevateBio has made eye-popping financing rounds routine, Life Edit formed separate partnerships with Moderna and Novo Nordisk in quick succession last year. → Acumen Pharmaceuticals ’ regulatory affairs leader Janice Hitchcock will retire “at the end of the year,” and Amy Schacterle has been named chief regulatory officer & head of quality at the Alzheimer’s biotech. Schacterle and Acumen president/chief development officer Jim Doherty were colleagues at Sage Therapeutics — Schacterle recently left Sage as part of the latest wave of job cuts after the company said it would no longer develop zuranolone for major depressive disorder. Acumen is testing its monoclonal antibody sabirnetug in patients with early Alzheimer’s. → The latest hires at Dublin-headquartered SynOx Therapeutics are based in the US: Medical chief Elyse Seltzer held multiple roles at GSK and is the former chief development officer at UroGen Pharma , while chief commercial officer Robert Francomano was appointed to the same position at Stemline Therapeutics and Sellas Life Sciences . “We are thrilled to welcome Elyse and Robert to the SynOx leadership team as we continue to work to strategically build out our presence within the key US market,” CEO Ray Barlow said in a statement . SynOx’s $92 million Series B includes a $17 million extension from Gilde Healthcare . → MaaT Pharma has recruited Eric Soyer to succeed Siân Crouzet as finance chief. Crouzet spent the last eight years as CFO and will now be MaaT Pharma’s chief of staff. Soyer had been CFO and COO at another French biotech, Erytech Pharma . His new company’s lead program MaaT013 is in a Phase 3 study for acute graft-versus-host disease. → Frits van Alphen has replaced Gerald Parzmair as chief development officer of Memo Therapeutics , a Swiss biotech that pulled together a total of $49 million for its Series C. After eight years at Novartis , van Alphen would go on to be CMO of Vifor Pharma from 2008-13 and Swiss-based Inositec , the undercard in Vifor’s M&A spree that included Sanifit in late 2021. He also worked for Roche as global head of product development excellence in between these two CMO gigs. → Synthetic lethality player Tessellate BIO has selected Lara Boyd as CBO. Boyd had a six-year run with Takeda partner F-star Therapeutics and was elevated to VP, head of business development & corporate strategy in May 2023. Former F-star boss Eliot Forster chairs the board at Tessellate BIO, which raised $8 million in seed funding from BioGeneration Ventures and Forbion . → La Jolla, CA-based I&I biotech CalciMedica has tapped Stephen Bardin as CFO, replacing interim finance chief Daniel Geffken . Earlier this year, Peer Review covered Bardin’s departure as CFO of atai Life Sciences , a position now held by Anne Johnson . He’s also worked for Myovant Sciences as director of corporate development and BridgeBio as SVP of finance and operations. → Joe Truluck has turned in his resignation as CFO of Adial Pharmaceuticals , and Vinay Shah will replace him on Nov. 16. We told you about Shah’s last CFO appointment at Virpax Pharmaceuticals in June 2023 and he’s had the same title at Aravive . Truluck will stay with Adial as a consultant until March 31. → Claudia Lopez has joined Seattle-based breast cancer biotech Atossa Therapeutics as VP, clinical product development. Lopez led the clinical development team at another AbbVie M&A pickup , Landos Biopharma , and the 16-year Takeda vet also spent two years with Arena Pharmaceuticals . → Tony Gibney has been named chairman of the board at Clearside Biomedical , which unspooled positive Phase 2b data last month for its suprachoroidal injection of axitinib called CLS-AX in patients with wet AMD. Gibney tackled the role of chief business & strategy officer at Iveric Bio until it was sold to Astellas last year for $5.9 billion. → Radiotherapy specialist Actinium Pharmaceuticals has elected June Almenoff to the board of directors. Almenoff, a GSK alum and the ex-president/CMO at Furiex Pharmaceuticals , is also on the boards of Avalo Therapeutics and Tenax Therapeutics . → Heron Therapeutics has reserved a seat on its board of directors for Liquidia CFO and COO Michael Kaseta . Before his gig with Liquidia, Kaseta was CFO at Aerami Therapeutics and Aralez Pharmaceuticals , as well as North American CFO, global services over a decade with Sanofi .

Partnerships will employ Vaccinex’s ActivMAb® platform for viral display of complex antigens to enable antibody discoveryROCHESTER, N.Y., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the signing of several proprietary project agreements with Amgen, Merck, Chugai, Absci, Gigagen (Grifols), Merus, Soleil, ThirdArc and Incyte, employing Vaccinex’s ActivMAb® technology to generate antibodies to complex antigen targets. In addition, Vaccinex has signed agreements to provide Charles River Labs, OmniAb, Adimab and other undisclosed strategic partners with materials to facilitate their antibody discovery programs using transgenic animal species for immunization or very large synthetic antibody libraries. The financial terms of the agreements are undisclosed. Vaccinex’s proprietary ActivMAb® Technology enables expression of functional, properly folded complex proteins such as GPCRs and Ion Channels on the relatively simple membrane of poxvirus providing a source of antigen for various antibody discovery strategies. These strategies may involve development of antibody and antibody-based immunotherapies including bi-specifics, antibody drug conjugates (ADC), CAR-T cells, T cell engagers, etc. “Our technology is a powerful component of antibody discovery strategies targeting complex membrane proteins and enables both our own R&D efforts and those of our partners,” said Ernest Smith, Chief Scientific Officer of Vaccinex. “These agreements and partnerships with established companies underscore ActivMAb’s unique ability to address previously hard to drug targets in a format ideally suited for antibody discovery.” Vaccinex will present data and examples of successful antibody discovery campaigns against potential oncology targets using the ActivMab Technology at the Society for Immunotherapy of Cancer’s 29th Annual Meeting held November 8-10, 2024, in Houston, TX. MeetingSITC 39th Annual MeetingDate:Saturday, Nov. 9, 2024Location:Exhibit Halls A B George R. Brown Convention CenterPoster Title:Discovery of high affinity functional antibodies specific for CXCR5, P2X7 and other multi-pass membrane receptorsPoster Number1100PresenterElizabeth Evans, PhD, Chief Operating Officer, Vaccinex, Inc. About ActivMAb®ActivMAb is a proprietary antibody discovery platform developed by Vaccinex with unique capabilities for important multi-pass membrane targets such as G-protein-coupled receptors (GPCRs) and ion channels. The ActivMAb technology has multiple applications including discovery of antibodies specific for complex membrane antigens, discovery of antibodies with optimized developability, and protein optimization for expression and activity. Its novel capabilities enable selection of unique antibody drugs against difficult high-value targets, including multi-pass membrane proteins against which small molecule drugs have demonstrated low efficacy or high toxicity. The first clinical candidate selected through use of this technology (CHS-114, a fully human monoclonal antibody targeting CCR8), is in clinical development for cancer immunotherapy by Coherus Biosciences, Inc. About Vaccinex Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating slowly progressive neurodegenerative diseases and cancer through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes triggers damaging inflammation in chronic diseases of the brain and prevents infiltration and activation of immune cells in tumors. Pepinemab is being studied as a monotherapy in the Phase 1b/2 SIGNAL-AD study in Alzheimer’s Disease, and the Company has previously published promising Phase 2 data in Huntington’s disease. Because it is well-tolerated, pepinemab could be an important contributor to combination therapy in AD. In oncology, pepinemab is being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma. Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA. Additional information about the study is available at: clinicaltrials.gov. KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. BAVENCIO®/avelumab is provided by Merck KGaA, Darmstadt, Germany, previously as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. Forward Looking StatementsTo the extent that statements contained in this presentation are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, ability to capitalize on, expectations and objectives with respect to the “Antigen Virus” applications of the ActivMab® platform, and other statements identified by words such as “believe,” “being,” “could,” “will,” “potential,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical studies and clinical trials, that interim and preliminary data may not be predictive of final results and does not ensure success in later preclinical studies and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, the possible delisting of our common stock from Nasdaq if we are unable to regain compliance with the Nasdaq listing standards, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in the Company’s annual year-end Form 10-K and subsequent filings with the SEC. Investor Contact Elizabeth Evans, PhD Chief Operating Officer, Vaccinex, Inc. (585) 271-2700 eevans@vaccinex.com

//   • “投早投小”，在前沿疗法还没成为热门的时候就开始布局； • 更偏长期型，没有特别界定明确的投资期和退出期限； • 格外注重科研成果转化； • Biotech高估值可能为将来的融资造成壁垒和障碍； • 新形势对创始人的适应性有新的要求。 维亚生物创新中心（Viva BioInnovator，以下简称“VBI”）自2017年创立以来，投资孵化了来自全球的90多家创新药企业，中国公司20逾家。最近，又一家VBI孵化的公司——聚焦难成药磷酸酶的Nerio，被勃林格殷格翰以最高13亿美金收购。 事实上，过去几年，维亚被投企业已成功地和Pharma、Biotech合作伙伴达成多起并购和BD交易，如：去年7月，脂肪酸链siRNA递送的DTx Pharma创立仅四年，就以首付5亿美金、最高10亿美金的总额与诺华达成收购协议；聚焦人工智能抗体发现的Totient被Absci并购；聚焦多肽偶联核药的Focus-X被辐联并购，等等。 据维亚生物首席创新官兼VBI负责人戴晗博士介绍，目前所投公司共计有200多条管线在持续推进，近40条管线最终进入了临床的不同阶段，部分早期孵化企业的研发项目顺利推进到了3期临床。 还没热门之前开始布局 研发客：VBI投资孵化的兴趣点和和创新投资模式是什么？ 戴晗： 在生物医药领域，VBI主要关注和寻找来自全球的、创新性较强、竞争壁垒较高的临床前管线或平台进行投资孵化，对于技术类型或治疗领域没有特别具体的限制。投资阶段聚焦在种子轮到A轮。总结起来就是“投早投小”，对于如siRNA、核药、XDC等前沿疗法，我们在其还没成为热门领域的时候就已经开始布局了。 维亚生物本身作为一家CRO公司，不同于一般药企的风险投资（CVC）是出于扩充自身管线的考虑，我们主要通过业务协同为这些早期项目赋能，再以BD或收并购等方式退出，寻求财务回报。 戴晗 所以我们的投资模式除了现金投资，还有服务换股权（EFS）模式。EFS指维亚通过向被投公司提供孵化和CRO服务，按一定价格折算成等值的投资金额，获得被投公司股权。该模式的优势一方面是可以减轻早期创业公司的现金流压力，同时维亚可以分享经验和资源，深度参与和支持被投公司的发展，实现双赢。 对于某家公司实际选择何种投资方式，要看我们的相关研发能力是否和被投企业的实际需求相匹配，在前期双方接触过程中我们的EFS部门就会和被投企业的研发团队进行深入交流。 在投资周期上也和一般的投资机构不同，我们更偏长期型，没有特别界定明确的投资期和退出期限，我们有耐心去长期陪伴企业成长。 研发客：VBI通过哪些渠道找到项目？ 戴晗： 首先是通过VBI同事和客户的个人关系网，去联系一些工业界出来创业的高管或科学家，帮助他们评估项目的可行性和架构公司。 由于VBI专注于提早布局早期管线或平台，所以格外注重科研成果转化。我们会和中国、美国和欧洲的许多高校、研究所的技术转移办公室去做很多互动，从源头接触这些创新科研成果，帮助他们做评估和转化。 还有就是与外部的孵化器、加速器和投资机构长期的互动与合作。例如，VBI也是强生创新孵化器（JLABS）投资中心的成员，同他们合作一方面是为了建立资源网络，可以相互推荐项目，另外也是为了发挥各自的优势共同投资孵化项目。VBI专注于早期投资，退出后希望交好接力棒，让好的项目可以继续得到支持。 研发客：VBI具体能为被投公司带来哪些帮助和支持？ 戴晗： 创新项目进入VBI孵化体系后，可以获得软硬件多重服务。硬件方面包括仪器实验设备、物理空间，软件包括VBI技术服务团队。 早期研发阶段的创新企业规模小，VBI通过EFS模式会实际负责很多管线的研发，用我们的经验加速管线推进。 同时，VBI通过自身产业资源优势，结合内外部资源来支持创新项目和企业。VBI在孵化投资中与企业充分合作交流，例如通过推出高峰会、Demo Day等系列活动，帮助其完成进一步的融资对接、和跨国公司合作、谈判交易、高管招募等事项。 怎样的估值有利于发展 研发客：您如何看待目前生物医药行业充满挑战的生存环境？Biotech该如何应对？ 戴晗： 任何行业的兴起和发展可能都会经历从资源大量涌入到逐渐回归理性的周期变化。过去几年，国内二级市场、IPO的变化、外资撤离等因素的确造成生物医药企业的投融资变得相对困难，但从好的一面来看，这有利于社会资源和行业资源的再分配和重组。过程虽然比较痛苦，但长期来看有利于产业的良性发展。 泡沫粉碎后的优胜劣汰，也让我们看到曾经涌入医药行业的大量资源造就了一批具有实力的本土公司，从研发端到临床端的能力非常国际化，很多产品是可以走上国际舞台进行PK的。不同的是，以前大家可能更倾向于自己研发，希望做成上市公司，如今环境相对艰难，大家愿意开放心态去探索和尝试多元化的合作交易模式。 如前不久业内讨论较多的NewCo模式，企业通过“造船出海”来借力海外的资金。我了解到，国内的一些基金也开始考虑用同样的方式找到好的标的组成公司去海外孵化，未来这样的案例可能会越来越多。 其实包括大药厂在内，任何一家公司的资源和能力边界都是有限的，通过BD或收并购的方式可以将管线国际化，通过外部合作也可以更好的加速和赋能项目的推进，同时带来一定的现金流。 在条件有限的情况下，开源节流精简管线后可以更聚焦自己最擅长的事。最终不论是以何种方式，产品如果能够成功都可以创造社会价值和经济价值。 研发客：医药行业大额交易频发，是否存在估值和实际价值不对等的情况? 戴晗： Biotech公司的估值很多时候是理论型和经验型相结合的结果。比如大家会从管线的价值，未来潜在的市场营收去做NPV或DCF的推算，但推算结果的准确度往往比较低。对于公司，除了管线，还要从平台、创始团队等其他维度来评价。 同一公司在不同时期的估值也可能不同，比如前几年的ADC和最近的GLP-1，在风口上的公司会有一定程度的溢价。很多时候公司的估值会在当时的阶段去和一些同类公司对标。 在实际的投资谈判中，主观的因素则更大，当时的供求关系会影响谈判结果，如壁垒比较高的核药，因为相对稀缺容易产生溢价。处于风口上或稀缺的公司，溢价在所难免。价值和价格一定程度上会有偏离是正常的，但过分偏离肯定不是特别健康的情况。有经验的、理性的投资人会觉得高估值有时未必是好事，可能为将来的融资造成壁垒和障碍。 对创始人提出新要求 仅2021年一年间，VBI就评估了979个项目，最终投了27个，筛选率约为3%。与众多创业公司深度互动后戴晗发现，Biotech能够穿越行业低迷期需要一些特殊的能力。 研发客：可以持续生存并发展良好的Biotech公司有哪些特点？ 戴晗： 医药企业的价值本源还是其管线是否具有差异化的优势。 此外，团队非常关键，再好的管线都需要人的运作，以保证顺利、快速高效将其往前推进。评估团队要看其过往经验和现在要做的事是否匹配，互补性和执行力如何。有时特别资深的行业高管去到一个陌生的领域，未必好过一个不如其资深但相关经验更丰富的人。 创始人本身的开放性和灵活度也很重要。具有这样特点的创始人可以兼容并包，把优秀的人才和行业资源凝聚在身边，并充分调动起来。 外资的撤退使得很多国内公司要去考虑通过与政府招商项目或政府引导的产业基金互动来拿到资金，这对创始人的适应性提出了新的要求。与外资的沟通偏市场型，他们更重视直接的财务回报。与政府沟通需关注其引导和促进地方产业发展的需求，会涉及一些地方性的要求，比如总部搬迁到当地、在当地建设厂房等。其财务要求不太容忍高风险，但对财务回报的要求相对较小。 所以创始人能否找到匹配公司发展诉求，既在战略上协同，又能在资源互补的投资方会直接影响到企业的生存与发展。 编辑 | 姚嘉 yao.jia@PharmaDJ.com  总第2221期 访问研发客网站，深度报道和每日新闻抢鲜看 www.PharmaDJ.com